Increasing evidence indicates that there is a correlation between papillary thyroid carcinoma (PTC) prognosis and the immune signature. Our goal was to construct a new prognostic tool based on immune genes to achieve more accurate prognosis predictions and earlier diagnoses of PTC.
The 493 PTCs samples and 58 tumor-adjacent normal tissues were obtained from The Cancer Genome Atlas database (TCGA). Immune genes were obtained from the ImmPort database. First, this cohort was randomly divided into training cohort and testing cohort. Second, the differentially expressed (DE) immune genes from the training set were used to construct the prognostic model. Then, the testing and entire data cohorts were used to validate the model, and the data were analyzed to determine the correlation of the clinical prognostic model with immune cell infiltration and expression profiles of human leukocyte antigen (HLA) genes. Finally, an analysis of the gene ontology (GO) annotation was performed.
A total of 189 upregulated and 128 downregulated DE immune genes were identified. We developed and validated a three-immune gene model for PTC that includes Hsp70, NOX5, and FGF23. This model was demonstrated to be an independent prognostic variable. In addition, the overall immune activity of the high-risk group was higher than that of the low-risk group.
We developed and validated a three-immune gene model for PTC that includes HSPA1A, NOX5, and FGF23. This model can be used as a validated tool to predict outcomes in PTC.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Papillary thyroid carcinoma
The Cancer Genome Atlas database
Human leukocyte antigen
Immune-related gene signature
The Gene set enrichment analysis
Area under the ROC curve
Heat shock protein family A (Hsp70) member 1A
NADPH oxidase 5
Fibroblast growth factor 23
Tumor immune microenvironment
Alzahrani AS, Xing M (2013) Impact of Iymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND. Endocr Relat Cancer 20:13–22
Omry-Orbach G (2016) Risk stratification in differentiated thyroid cancer: an ongoing process. Rambam Maimonides Med J 7(1):e0003
Luster M, Clarke SE, Dietlein M et al (2008) Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 35:1941–1959
Zhong LK, Gan XX, Deng XY et al (2020) Potential five-mRNA signature model for the prediction of prognosis in patients with papillary thyroid carcinoma. Oncol Lett 20:2302–2310
Kim K, Jeon S, Kim TM, Jung CK (2018) Immune gene signature delineates a subclass of papillary thyroid cancer with unfavorable clinical outcomes. Cancers 10
Na KJ, Choi H (2018) Immune landscape of papillary thyroid cancer and immunotherapeutic implications. Endocr Relat Cancer 25:523–531
Antonelli A, Ferrari SM, Fallahi P (2018) Current and future immunotherapies for thyroid cancer. Expert Rev Anticancer Ther 18:149–159
Han J, Chen M, Wang Y et al (2018) Identification of biomarkers based on differentially expressed genes in papillary thyroid carcinoma. Sci Rep 8:9912
Yang H, Zhang X, Cai XY et al (2017) From big data to diagnosis and prognosis: gene expression signatures in liver hepatocellular carcinoma. PeerJ 5:e3089
Li B, Cui Y, Diehn M, Li R (2017) Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non-small cell lung cancer. JAMA Oncol 3:1529–1537
Tomczak K, Czerwińska P, Wiznerowicz M (2015) The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contempor Oncol 19:68–77
Gong Y, Zou B, Chen J et al (2019) Potential five-MicroRNA signature model for the prediction of prognosis in patients with Wilms Tumor. Med Sci Monitor 25:5435–5444
Fan Q, Liu B (2016) Identification of a RNA-Seq based 8-long non-coding RNA signature predicting survival in esophageal cancer. Med Sci Monitor 22:5163–5172
Tian S, Meng G, Zhang W (2018) A six-mRNA prognostic model to predict survival in head and neck squamous cell carcinoma. Cancer Manage Res 11:131–142
Yoshihara K, Shahmoradgoli M, Martínez E et al (2013) Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 4:2612–2612
Yu G, Wang LG, Han Y, He QY (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16:284–287
Varricchi G, Loffredo S, Marone G, Modestino L, Galdiero MR (2019) The immune landscape of thyroid cancer in the context of immune checkpoint inhibition. Int J Mol Sci 20:3934
Scieglinska D, Piglowski W, Chekan M, Mazurek A, Krawczyk Z (2011) Differential expression of HSPA1 and HSPA2 proteins in human tissues; tissue microarray-based immunohistochemical study. Histochem Cell Biol 135:337–350
Faria CC, Fortunato RS (2020) The role of dual oxidases in physiology and cancer. Genetics Mol Biol 43:e20190096
Li DJ, Fu H, Zhao T, Ni M, Shen FM (2016) Exercise-stimulated FGF23 promotes exercise performance via controlling the excess reactive oxygen species production and enhancing mitochondrial function in skeletal muscle. Metabolism 65:747–756
Gan X, Shen F, Deng X et al (2020) Prognostic implications of the BRAF-V600(E) mutation in papillary thyroid carcinoma based on a new cut-off age stratification. Oncol Lett 19:631–640
Lin CH, Chang CK, Shih CW, Li HY, Shih SR (2019) Serum fibroblast growth factor 23 and mineral metabolism in patients with euthyroid Graves’ diseases: a case-control study. Osteoporos Int 30:2289–2297
Yu H, Huang X, Liu X et al (2013) Regulatory T cells and plasmacytoid dendritic cells contribute to the immune escape of papillary thyroid cancer coexisting with multinodular non-toxic goiter. Endocrine 44:172–181
Treilleux I, Blay JY, Bendriss-Vermare N et al (2004) Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 10:7466–7474
Cunha LL, Morari EC, Guihen AC et al (2012) Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma. Clin Endocrinol 77:918–925
Kim BH (2013) The expression of tumor-associated macrophages in papillary thyroid carcinoma. Endocrinol Metab 28:178–179
Fang W, Ye L, Shen L et al (2014) Tumor-associated macrophages promote the metastatic potential of thyroid papillary cancer by releasing CXCL8. Carcinogenesis 35:1780–1787
Chu D, Dong X, Shi X, Zhang C, Wang Z (2018) Neutrophil-based drug delivery systems. Adv Mater (Deerfield Beach, Fla.) 30:e1706245
Walker C, Mojares E, Del Río Hernández A (2018) Role of extracellular matrix in development and cancer progression. Int J Mol Sci 19(10):3028
Thanks to Professor Bo Xu for this design.
This research was supported by Guangzhou medicine and healthcare technology projects (20141A011011, 20151A011007, and 20161A011008).
Conflict of interest
The authors reported no proprietary or commercial interest in any product mentioned or concept discussed in this article.
All data of the study were obtained from The Cancer Genome Atlas (TCGA) database and have obtained ethical approval.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Gan, X., Guo, M., Chen, Z. et al. Development and validation of a three-immune-related gene signature prognostic risk model in papillary thyroid carcinoma. J Endocrinol Invest (2021). https://doi.org/10.1007/s40618-021-01514-7
- Immune gene
- Risk model
- Papillary thyroid carcinoma